Ibrexafungerp Citrate is Used for preventing and treating recurrent and acute vulvovaginal candidiasis in adult and post-menarchal pediatric females. It was first introduced by Scynexis Inc in its drug Brexafemme on Jun 1, 2021.

Ibrexafungerp Citrate Patents

Given below is the list of patents protecting Ibrexafungerp Citrate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Brexafemme	US10174074	Salts and polymorphs of SCY-078	Jan 19, 2035	Scynexis
Brexafemme	US10370406	Salts and polymorphs of SCY-078	Jan 19, 2035	Scynexis
Brexafemme	US10927142	Salts and polymorphs of SCY-078	Jan 19, 2035	Scynexis
Brexafemme	US11534433	Antifungal agents with enhanced activity in acidic pH	Jun 10, 2039	Scynexis
Brexafemme	US8188085	Antifungal agents	Aug 28, 2030	Scynexis

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳